Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elanco Animal Health's revenue for the
three
months ended in Jun. 2026 was MXN23,870 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was MXN90,049 Mil.
Elanco Animal Health's Revenue per Share for the
three
months ended in Jun. 2026 was MXN47.18.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was MXN179.47.
During the past 12 months, the average Revenue per Share Growth Rate of Elanco Animal Health was 11.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 1.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 2.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 1.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 11 years, Elanco Animal Health's highest 3-Year average Revenue per Share Growth Rate was 6.60% per year. The lowest was -3.00% per year. And the median was 1.10% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Elanco Animal Health's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elanco Animal Health Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elanco Animal Health's Revenue distribution charts can be found below:
* The bar in red indicates where Elanco Animal Health's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN90,049 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elanco Animal Health (MEX:ELAN) has a Revenue of MXN90,049 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Elanco Animal Health and its competitors.
Is Elanco Animal Health's Revenue too high?
Elanco Animal Health's current Revenue is MXN90,049 Mil. Overall, Elanco Animal Health has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Elanco Animal Health's Revenue compare to ALKS and LQDA?
Elanco Animal Health's Revenue of MXN90,049 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Elanco Animal Health and its competitors. Elanco Animal Health's current Revenue is MXN90,049 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elanco Animal Health stock overvalued right now?
Elanco Animal Health (MEX:ELAN) has a current Revenue of MXN90,049 Mil. The stock's GF Value™ is MXN294.93, compared to a current price of MXN392.00 — trading 32.9% above its estimated fair value. The current Revenue is MXN90,049 Mil. Elanco Animal Health's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Elanco Animal Health (MEX:ELAN), the current Revenue is MXN90,049 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elanco Animal Health (MEX:ELAN) Overvalued in 2026?
Based on GuruFocus' analysis, Elanco Animal Health stock appears to be overvalued.
The current stock price of MXN392.00 is trading 32.9% above its estimated GF Value™ of MXN294.93.
Key valuation signals for MEX:ELAN:
Revenue: MXN90,049 Mil
GF Value™: MXN294.93 vs. price of MXN392.00 (32.9% above fair value)
No single metric tells the full story. See the MEX:ELAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
69GF Score
Get the complete analysis for MEX:ELAN
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ELAN has been successfully added to your 
